Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.
The post Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic appeared first on MedCity News.
New data is now available for public use that helps inform the history and current state of the certified health IT market. We explore that […]
Democrats are jumping into the fray to voice their disapproval about Secretary of Health and Human Services Robert F. Kennedy Jr. and the broader debate […]
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Potential cuts to Medicaid under […]